Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT103 and Pembrolizumab in STK11 Mutant NSCLC
NCT07017829Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of GT103 in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
GT103
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07017829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017829.